ConvaTec (CTEC.L) — Company Research

Last Updated: 4 May 2026

ConvaTec Group plc (LSE: CTEC) is a FTSE 100 medical-products company focused on chronic-condition therapies across four care categories — Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care — with FY25 (year ended 31 December 2025) revenue of US$2,439 m (+6.5% reported, +6.4% organic ex-InnovaMatrix) reported on 24 February 2026. FY25 adjusted operating profit rose 12.1% to US$544 m, adjusted operating margin expanded ~110 bp to 22.3%, and adjusted diluted EPS climbed 16.0% to 17.6 cents; the full-year dividend was raised 13% to 7.244 cents and a US$300 m share buyback was completed. The dominant strategic story is the InnovaMatrix headwind: the US Centers for Medicare and Medicaid Services (CMS) set the 2026 reimbursement rate for ConvaTec's pig-placental skin-substitute InnovaMatrix at US$127.28/cm² effective 1 January 2026 — an ~80% reduction that drove a US$72 m non-cash impairment of the Triad intangible and a guided FY26 InnovaMatrix revenue of only ~US$20 m (vs US$69 m in FY25). On 3 February 2026 the FDA also issued a Warning Letter to subsidiary Unomedical (Reynosa, Mexico) covering quality-management procedures for infusion sets — no production restrictions, no recall. Despite both, management raised the medium-term (2027+) organic revenue growth target to 6–8% (from 5–7%) and unveiled the new "Accelerate" strategy at a 9 April 2026 Capital Markets Day. CEO is Jonny Mason (permanently appointed in November 2025 following the death of Karim Bitar on 27 October 2025); CFO is Fiona Ryder. The shares closed 1 May 2026 at 210.00p with a market cap of ~£4.10 bn, trading near the bottom of the 52-week range (207.40–311.20p) after a ~33% drawdown from the June 2025 highs. For live price action see live charts; for upcoming earnings dates the economic calendar; community discussion is on the forum.

1. Company Snapshot

Company	ConvaTec Group plc
Ticker	LSE: CTEC (FTSE 100; ISIN GB00BD3VFW73; ADR: CNVVY)
Sector / Industry	Healthcare — Medical Equipment & Supplies / Chronic-condition medical products
HQ	20 Eastbourne Terrace, London W2 6LG, United Kingdom
CEO	Jonny Mason (permanent CEO since 12 November 2025; previously CFO from 31 January 2022; interim CEO 4 August 2025)
CFO	Fiona Ryder (Group Financial Controller; appointed permanent CFO November 2025; previously Interim CFO from August 2025)
Chair	Dr John McAdam
Founded	1978 (as a corporate venture inside Bristol-Myers Squibb — commercialising hydrocolloid wound-care technology)
Ownership history	BMS (1978–2008) → Nordic Capital + Avista Capital Partners ($4.1 bn LBO, 2008) → Unomedical merged in (2008) → LSE IPO October 2016 (largest European healthcare IPO in 20+ years; raised ~$1.8 bn)
Index membership	FTSE 100 (since December 2016)
Reporting currency	US Dollar (USD); listed and dividends declared in pence sterling
Fiscal year end	31 December
Employees	~10,000+ across more than 100 countries
Care categories	Advanced Wound Care, Ostomy Care, Continence Care, Infusion Care
Share price (1 May 2026 close)	210.00p
52-week range	207.40p (intraday low, late April 2026) – 311.20p (June 2025)
Shares outstanding	~1.95 bn (post US$300 m FY25 buyback; ~94.9 m shares held in treasury)
Market cap	~£4.10 bn
FY25 revenue	US$2,439 m (+6.5% reported)
FY26 guidance	Organic revenue growth ex-InnovaMatrix 5–7%; adj operating margin ≥23.0%; double-digit adj EPS growth
Annual dividend (FY25)	7.244 cents (interim 1.877c paid; final 5.367c recommended) — +13% YoY
2026 AGM	14:00 BST, Thursday 21 May 2026, 20 Eastbourne Terrace, London W2 6LG
Next results	H1 2026 interim results — expected late July 2026 (FY24 H1 was reported 29 July 2025)

2. Bull Case vs Bear Case

Bull Case	Bear Case
Chronic-care annuity model: ~97% of revenue tied to chronic conditions requiring continuous patient use; high renewal rates and resilient through economic cycles. FY25 organic growth ex-InnovaMatrix +6.4% across all four categories with each line growing 4%+.	InnovaMatrix collapse: CMS set the 2026 reimbursement rate at US$127.28/cm² (~80% reduction). FY25 InnovaMatrix revenue dropped 29.7% to US$69 m; FY26 guidance is only ~US$20 m. The Triad acquisition was up to US$450 m all-in — a US$72 m non-cash impairment was booked in FY25.
Margin compounder: adjusted operating margin expanded ~460 bp from FY21 (17.7%) to FY25 (22.3%), and management has guided FY26 to ≥23.0% with a medium-term mid-20s (24–26%) target. Adj diluted EPS +16% in FY25.	FDA Warning Letter (3 February 2026) at Unomedical's Reynosa, Mexico facility for quality-management failures around infusion-set complaint handling, validation and 30-day adverse-event reporting. No production restriction but it adds remediation cost and execution risk in the highest-growth segment.
Pipeline is the richest in ConvaTec's history: ConvaFoam (already scaling), Aquacel ConvaFiber (US/EU cleared July 2025; H1 26 launch), ConvaVac single-use NPWT (H2 26), ConvaNiox nitric-oxide dressing (EU/UK approved; scaling 2027), Flexi-Seal Air, Natura Body, GentleCath Air Pocket. Eight launches scheduled 2026–27.	Stock under pressure: 1 May 2026 close 210.00p is —33% off the June 2025 high of 311.20p. The shares have lagged the FTSE All-Share by ~33% over the past year and trade near the 52-week low.
Infusion Care — the highest-growth category — is delivering: FY25 organic +12.5% to US$473 m, helped by extended-wear sets, the Beta Bionics iLet bionic-pancreas partnership and Neria Guard. Management has lifted the medium-term IC growth target to double-digit.	Net debt rose to US$1,330 m at end-FY25 (from US$1,058 m), pushing leverage to 2.0× adj EBITDA (from 1.8×) — in line with the 2.0× target but with less headroom for further bolt-on M&A. ConvaTec issued US$500 m of 5.3% 10-year senior notes.
Cash conversion and capital return: equity cash conversion 101%; FCF to equity (pre-growth-capex) US$362 m; full-year dividend +13%; US$300 m FY25 buyback completed. New "Accelerate" strategy unveiled 9 April 2026 reaffirmed 6–8% revenue, mid-20s margin, double-digit EPS and double-digit FCF/equity CAGR.	FX and US reimbursement risk: ~57% of revenue is Americas (mostly USD); ConvaTec reports in USD but is GBP-listed, exposing UK shareholders to GBP/USD swings. CMS skin-substitute policy (effective 1 Jan 2026) consolidated dozens of fragmented codes into a single site-neutral framework — further administrative pricing actions remain a risk for AWC.

3. What Does This Company Actually Do?

ConvaTec designs, manufactures and sells medical products for chronic conditions — principally chronic wounds, stomas (intestinal/urinary), incontinence, and diabetes (insulin infusion). Its products are mostly consumed (changed daily, weekly or every few days), so the business is a continuous-replacement annuity rather than capital equipment. ConvaTec was founded inside Bristol-Myers Squibb in 1978 to commercialise hydrocolloid wound dressings (the Aquacel and DuoDerm families), spun off via a private-equity LBO in 2008, and IPO'd on the London Stock Exchange in October 2016. The company reports in US dollars but is listed in pence sterling.

FY25 revenue mix (year ended 31 December 2025, US$2,439 m total):

Category	What it does	FY25 revenue	% of FY25	FY25 organic growth
Advanced Wound Care (AWC)	Hydrofiber dressings (Aquacel, Aquacel Ag, ConvaFoam), antimicrobial dressings, NPWT (Avelle, ConvaVac launching H2 26), wound biologics (InnovaMatrix skin substitute)	US$753 m	~30.9%	+1.9% reported / +4.1% ex-InnovaMatrix
Ostomy Care (OC)	Stoma pouches and accessories (Esteem Body, Natura, SenSura/Stomahesive); me+ patient-support programme	US$676 m	~27.7%	+4.5%
Continence Care (CC)	Intermittent urinary catheters (GentleCath, Cure Medical), Flexi-Seal faecal management	US$537 m	~22.0%	+6.6%
Infusion Care (IC)	Insulin pump infusion sets and insertion devices (inset, contact detach, Neria Guard, extended-wear; sets for Beta Bionics iLet bionic pancreas)	US$473 m	~19.4%	+12.5%
Group total	—	US$2,439 m	100%	+4.8% organic / +6.4% ex-InnovaMatrix

Geographic mix (FY24 disclosure, broadly stable in FY25): Americas ~57%, EMEA ~29%, Asia-Pacific ~14%. The US is the largest single country and the source of most of the InnovaMatrix exposure as well as the bulk of the Infusion Care customer base (Tandem, Beta Bionics, Insulet ecosystem).

Customer/channel: ConvaTec sells primarily into hospitals and acute care, durable medical equipment (DME) distributors, retail pharmacy and home-care. The me+ programme (ostomy patient support) and ME+™ recovery (post-surgical) are central to direct-to-patient adherence and reorder rates.

4. The Business Model

• Recurring-consumable economics: Wound dressings are changed every 1–7 days; ostomy pouches every 3–7 days; intermittent catheters multiple times per day; insulin infusion sets every 2–3 days (extended-wear up to 7). Each chronic patient generates predictable recurring revenue for years, often decades.
• ~97% chronic-condition mix: Disclosed FY23 data showed ~97% of revenue is chronic-condition-tied — the legacy strategic shift away from acute-care commoditised products has been the single biggest driver of margin progression since the Karim Bitar (FY19+) era.
• Margin trajectory: Adjusted operating margin has expanded from 17.7% (FY21) to 22.3% (FY25) — ~460 bp in four years — on better mix (chronic-care, higher-priced biologics like InnovaMatrix), ConvaTec Manufacturing System productivity, and operating leverage. FY26 guidance is ≥23.0% (a ~70 bp YoY step despite ~20 bp of incremental tariff costs in H1 26). Medium-term target raised to mid-20s.
• R&D as % of sales: Roughly doubled from 2.7% in 2018 to ~4.6% by 2023 and continues to step up. Management's FY24 disclosure was that "products less than five years old" accounted for ~30% of revenue — the goal of the FISBE strategy completed in 2025 and now succeeded by the "Accelerate" plan launched 9 April 2026.
• Capex: Total FY25 capex US$185 m (growth $121 m + operational $64 m); FY26 guided US$200–230 m total with growth capex US$135–165 m. Capacity investment is concentrated in Mexico (infusion sets), Czech Republic (continence) and Slovakia (ostomy/wound).
• Subsidies / regulatory credits: No material exposure to government subsidies or regulatory credits. Revenue is from product sales reimbursed via traditional medical insurance, Medicare/Medicaid, NHS, and other public/private payers.
• Reimbursement dependency: The InnovaMatrix CMS pricing change is the textbook example of administrative-pricing risk. CMS LCDs (Local Coverage Determinations) on skin substitutes were postponed in 2025 then implemented from 1 January 2026 with a single national rate — this is the dominant FY26 P&L variable.
• Capital allocation: Target leverage 2.0× adj EBITDA. FY25 deployment: US$300 m share buyback (94.9 m shares to treasury); US$140 m dividends paid; debt issuance of US$500 m of 10-year 5.3% senior notes to extend the maturity profile.

5. Financial Health

Five-year financials (calendar fiscal year ended 31 December; figures in US$ m unless stated).

Metric	FY21	FY22	FY23	FY24	FY25
Revenue ($m)	2,038	2,073	2,142	2,289	2,439
Reported YoY	+9.9%	+1.7%	+3.3%	+6.9%	+6.5%
Organic revenue growth	+5.3%	+5.6%	+7.4%	+7.7%	+4.8% (+6.4% ex-InnovaMatrix)
Gross profit ($m)	1,124	1,117	1,207	1,288	1,372
Adj operating margin	17.7%	19.5%	20.2%	21.2%	22.3%
Adj operating profit ($m)	~361	~404	~432	~485	544
Reported operating profit ($m)	231	245	293	352*	316
Reported net income ($m)	118	63	130	191	175
Adj diluted EPS (cents)	~12.5	~13.4	~14.2	15.2	17.6
Free cash flow ($m)	212	138	238	305	335
Capex ($m)	~95	~110	~115	122	185
Dividend per share (US cents)	5.806	5.972	6.108	6.412	7.244
Net debt ($m)	1,003	1,028	914	1,058	1,330
Leverage (x adj EBITDA)	2.1×	2.0×	1.6×	1.8×	2.0×

* FY24 reported operating profit benefited from one-off gains; FY25 was burdened by the US$72 m InnovaMatrix Triad-intangible impairment (CMS reimbursement reset).

Half-yearly trajectory (FY25 split — full quarterly disclosure is not provided): H1 2025 revenue was US$1,179 m (+6.0% reported, +6.8% organic ex-InnovaMatrix). H2 2025 revenue therefore was ~US$1,260 m. Infusion Care H1 25 revenue was US$227 m (+13.7% reported, +14.1% organic). The FY25 H2 deceleration was driven primarily by the InnovaMatrix step-down (a sharper slowdown in H2 ahead of 1 January 2026 reimbursement reset) and a softer US AWC backdrop.

Balance sheet: Net debt at end-FY25 was US$1,330 m vs US$1,058 m at end-FY24 — the US$272 m increase reflects the US$300 m share buyback partially offset by free cash flow generation. Leverage is 2.0× adj EBITDA, in line with the company's 2.0× target. ConvaTec issued US$500 m of 10-year senior notes at 5.3% during FY25, extending the average debt maturity. Equity cash conversion in FY25 was 101% (FY24: 116%).

6. Valuation & Market Data

Share price (1 May 2026 close)	210.00p
52-week high	311.20p (June 2025)
52-week low	207.40p (intraday, late April 2026)
52-week price change	−19.17%
Shares outstanding	~1.95 bn (post US$300 m FY25 buyback)
Market capitalisation	~£4.10 bn (~US$5.13 bn at GBP/USD 1.25)
Enterprise value	~£5.18 bn (~US$6.48 bn)
Trailing P/E (StockAnalysis, 1 May 2026)	~32.86×
Forward P/E (FY26 consensus midpoint)	~14.41×
EV/EBITDA	~11.4×
EV/Revenue	~2.86×
P/Sales (TTM)	~2.26×
P/Book	~3.64×
Beta (5-yr)	0.79
50-day moving average	~230.7p
200-day moving average	~234.4p
Annual dividend per share (FY25 declared)	7.244 US cents (~5.79p at 0.80 GBP/USD)
Dividend yield	~2.53%
Payout ratio	~80% (Stockopedia, on reported EPS basis)
Free cash flow yield	~5.2% (FCF/equity ~US$362 m / market cap ~US$6.93 bn)
Reporting currency	USD (results); listed and dividends declared in pence sterling
Short interest (FCA short positions register, May 2026)	No disclosable net short position >0.5% of issued share capital reported on FCA register at 1 May 2026

7. What Are They Building / What's Coming?

• "Accelerate" strategy (Capital Markets Day, 9 April 2026): Successor to the FISBE plan that took ConvaTec to a chronic-care leader across all four categories. Reaffirmed medium-term targets: organic revenue growth 6–8% (raised from 5–7%); adj operating margin in the mid-20s (24–26%); double-digit adj EPS growth; double-digit FCF/equity CAGR. Underpinned by the strongest pipeline in company history.
• Aquacel ConvaFiber (H1 2026 launch): Next-generation Hydrofiber dressing; US, EU, UK and Australia regulatory clearance secured 24 July 2025. Engineered to maintain Aquacel Extra benefits (absorbency, intimate wound contact) while improving structural integrity on removal. Indicated for venous leg ulcers, diabetic foot ulcers, pressure injuries, surgical wounds and partial-thickness burns.
• ConvaVac (single-use NPWT, H2 2026): Single-use negative pressure wound therapy device, completing the AWC pipeline alongside ConvaFoam (already scaling) and InnovaMatrix.
• ConvaNiox (nitric-oxide dressing): EU/UK approval secured; revenue building from 2027.
• InnovaMatrix: CMS rate of US$127.28/cm² effective 1 January 2026 (~80% reduction). FY26 revenue guided ~US$20 m vs US$69 m FY25. Management expects volumes to build through 2026 as higher-cost competitors exit and as ConvaTec extends sales coverage and indications. US$72 m non-cash impairment of the Triad intangible was recognised in FY25.
• Ostomy Care pipeline: Flexi-Seal Air (faecal management); Natura Body (2027). Ostomy Care medium-term growth target raised to mid-to-high single digits (from mid single).
• Continence Care: GentleCath Air Pocket and GentleCath Air Set (intermittent catheters). The Cure Medical acquisition (March 2021) integrated; CMS catheter-code changes monitored.
• Infusion Care: Highest-growth segment (FY25 organic +12.5%). Beta Bionics iLet bionic-pancreas partnership using inset and contact detach sets continues to scale (note: the FDA Warning Letter is to ConvaTec subsidiary Unomedical, not Beta Bionics). Neria Guard, extended-wear infusion sets, and additional pump partnerships to come. Also note: a separate FDA Warning Letter was issued to Beta Bionics on 28 January 2026 regarding the iLet platform itself — ConvaTec is the supplier of infusion sets to that ecosystem.
• Capital return: US$300 m FY25 buyback completed; FY25 dividend +13% to 7.244 cents. Final dividend (5.367 cents) ex-date 16 April 2026, payable 28 May 2026.
• 2026 AGM: 14:00 BST, Thursday 21 May 2026 at 20 Eastbourne Terrace, London W2 6LG.

8. Competitive Landscape

ConvaTec competes in four overlapping but distinct global markets, each with its own oligopolistic structure:

• Ostomy Care — a ~US$3.47 bn global market (2025) growing at ~4.4% CAGR. The "big three" of Coloplast, Hollister and ConvaTec command the majority of share, with B. Braun and others sharing the long tail.
• Advanced Wound Care — a ~US$13.4 bn global market (2025), growing 7.6% CAGR to ~US$19.3 bn by 2030. Solventum (the May 2024 spin from 3M's healthcare business), Smith+Nephew, Mölnlycke, ConvaTec and Coloplast collectively hold ~45–50%; in the US, the top five (Smith+Nephew, Solventum, Mölnlycke, ConvaTec, Cardinal Health) hold ~24% of advanced wound care.
• Continence Care — intermittent catheters dominated globally by Coloplast, Hollister, ConvaTec (incl. Cure Medical) and B. Braun.
• Infusion Care — insulin-pump infusion sets. ConvaTec (via Unomedical) is the dominant global manufacturer with sets supplied to most major pump platforms including Medtronic, Tandem, Insulet (Omnipod competition is via patch-pump architecture which doesn't use infusion sets), and Beta Bionics iLet.

Peer	Listing	Care category overlap	Approx. market position
Coloplast (COLO B)	Copenhagen	Ostomy, Continence, Wound, Skin	#1 global ostomy ~28%; #1 intermittent catheter; ~DKK 27 bn revenue
Hollister (private)	Privately held (Hollister family / employee-owned)	Ostomy, Continence	#2 global ostomy ~22%; ~US$1.0 bn+ revenue (estimated)
ConvaTec (CTEC)	LSE	Wound, Ostomy, Continence, Infusion	~19.5% global ostomy; ~US$2.44 bn revenue FY25
Smith+Nephew (SN.)	LSE	Advanced Wound Care, Orthopedics, Sports Medicine	~6.8% US AWC; ~US$5.8 bn revenue (orthopaedics-led)
Solventum (SOLV)	NYSE	Wound, Skin Health, MedSurg	3M healthcare spin (April 2024); largest US AWC share; ~US$8.2 bn revenue
Mölnlycke (private)	Investor AB-owned	Advanced Wound Care, Surgical	Top-3 EU AWC; ~€2 bn revenue
B. Braun Melsungen (private)	Privately held (B. Braun family)	Ostomy, IV therapy, Surgical, Continence	~5% global ostomy; ~€9 bn group revenue
Cardinal Health (CAH)	NYSE	Distribution + private-label wound	Top-5 US AWC supplier

Competitive impact analysis — CMS skin-substitute rule: The CMS Local Coverage Determination (LCD) on skin substitutes effective 1 January 2026 consolidated dozens of fragmented payment codes into a single national rate. ConvaTec is the most directly hit large player given InnovaMatrix's biologic positioning, but the ruling is also a competitive headwind for Organogenesis, MiMedx, Smith+Nephew (Oasis biologics) and other amniotic-tissue producers. Management has flagged that "some higher-cost competitors may exit if the new pricing holds" — potentially leaving InnovaMatrix as one of the surviving products able to absorb the rate cut at scale. The dynamic mirrors prior CMS Part B reforms in oncology and dialysis where short-term revenue impairment was followed by share consolidation among the lowest-cost producers.

9. Leadership and Ownership

CEO succession: Karim Bitar, who joined ConvaTec as CEO in September 2019 and led the strategic pivot to chronic-care, took medical leave on 4 August 2025 and sadly passed away on 27 October 2025. Jonny Mason — CFO since 31 January 2022 — was named Interim CEO on 4 August 2025 and confirmed permanent CEO in November 2025. Fiona Ryder, the Group Financial Controller, was named Interim CFO and subsequently confirmed permanent CFO in the same November 2025 announcement.

CEO — Jonny Mason: Joined ConvaTec from Hilton Food Group (CFO 2018–2022). Prior senior finance roles at Sainsbury's, Asda and Coca-Cola Enterprises. Promoted from CFO to permanent CEO 12 November 2025.

CFO — Fiona Ryder: Group Financial Controller prior to August 2025 promotion to Interim CFO; confirmed permanent CFO in November 2025.

Chair: Dr John McAdam (longstanding non-executive Chair).

Top institutional shareholders (per recent disclosures): Capital Group Companies (~12.4%), BlackRock (~7.8%), Vanguard, Norges Bank, Standard Life Aberdeen, Lindsell Train. Top five institutional holders collectively own >35% of voting rights. Insider/director ownership is negligible (under 1%).

Recent PDMR transactions (RNS — selected):

Date	Insider	Role	Action	Shares	Price	Notes
16 Mar 2026	Jonny Mason	CEO	Sell-to-cover (vested LTIP)	291,149 sold; 270,355 retained	£2.344	Income tax & NI satisfaction; ~£681k gross sale
16 Mar 2026	Fiona Ryder	CFO	Sell-to-cover (vested LTIP)	~partial sold; 14,272 retained	£2.344	Income tax & NI satisfaction
12 Mar 2026	Various PDMRs	Director/PDMR	RNS Director/PDMR Shareholding notification	n/a	n/a	Routine
4 Sep 2025	Various PDMRs	Director/PDMR	RNS Director/PDMR Shareholding notification	n/a	n/a	Routine
2 Jun 2025	Various PDMRs	Director/PDMR	RNS Director/PDMR Shareholding notification	n/a	n/a	Routine

Aggregate trend: PDMR activity in 2026 has been dominated by routine sell-to-cover transactions on vested LTIP awards rather than discretionary open-market trades. There have been no disclosed open-market insider purchases in the trailing 12 months at the prevailing 207–240p price range despite the >30% drawdown from June 2025 highs.

10. Risks and Challenges

• InnovaMatrix / CMS reimbursement risk: CMS rate of US$127.28/cm² effective 1 January 2026 (~80% reduction); FY26 InnovaMatrix revenue guided ~US$20 m vs US$69 m FY25 (a 71% step-down). US$72 m Triad intangible impairment booked. Further administrative-pricing actions on skin substitutes or wider AWC categories remain a recurring risk; ConvaTec has cited this as a ~2% Group revenue headwind for FY26 (~3% in H1 26).
• FDA Warning Letter at Unomedical (3 February 2026): Reynosa, Mexico facility cited for inadequate complaint handling, inadequate validation of devices, and failure to report adverse events within the required 30 days. Concerns specifically tied to leaking infusion sets that can cause insulin under-delivery and risk of diabetic ketoacidosis; ~3,000 leak complaints prompted a corrective action in February 2025. The Warning Letter does not restrict production, marketing or distribution, but it is a remediation cost and reputational headwind in the highest-growth segment.
• FX / reporting currency: ConvaTec reports in USD but is GBP-listed and pays dividends in pence sterling; ~57% of revenue is from the Americas, but European costs (Slovakia, Czech, Denmark, UK) are euro and crown denominated. GBP/USD volatility directly impacts the pence-equivalent dividend and London-quoted earnings.
• FDA / MDR regulatory surface: Multi-product, multi-geography portfolio means a continuous compliance load — EU MDR transition is largely complete but has been a multi-year cost item; FDA inspections at any of the Mexico, Czech, Slovakia or Denmark sites are recurring risk events.
• Leadership transition: Karim Bitar (CEO 2019–2025) was the architect of the chronic-care pivot and the FISBE strategy that drove the 460 bp margin expansion. His passing on 27 October 2025 is a strategic continuity risk; the Mason/Ryder team has been with the company for several years but is newly in their permanent roles.
• Pipeline execution: ConvaFiber, ConvaVac, ConvaNiox, Flexi-Seal Air and Natura Body are all 2026–27 launches. The 6–8% medium-term growth target relies on these scaling on schedule and in the face of competing launches from Coloplast, Hollister, Smith+Nephew and Mölnlycke.
• Leverage: Net debt up to US$1,330 m / 2.0× adj EBITDA at end-FY25 (in line with target). The new US$500 m 5.3% senior notes extend maturities but carry a higher coupon than the legacy debt. Buyback cadence in FY26 may slow compared with FY25's US$300 m if leverage approaches the upper bound.
• China VBP risk: Volume-Based Procurement and tendering programmes in China have been a recurring headwind for medical-device peers (Coloplast, Smith+Nephew). Asia-Pacific is ~14% of ConvaTec revenue; specific China VBP impact has been smaller than for orthopaedics or stents but is not zero, particularly in continence and ostomy lines as those programmes expand.
• Competitive intensity in AWC: Solventum, Smith+Nephew and Mölnlycke are all investing in adjacent technologies; the InnovaMatrix biologic was meant to differentiate but the CMS reset has effectively neutralised the pricing premium. Hydrofiber (Aquacel) faces ongoing generic and private-label competition.
• Customer concentration in distribution: US AWC and continence care flow through DME/distribution networks; channel inventory adjustments at large distributors materially affected H2 2025 reported AWC growth (1.9% reported vs 4.1% organic ex-InnovaMatrix).
• Litigation / product liability: Routine for a medical-products company with this portfolio breadth; the FY25 Annual Report (published 10 March 2026) documents the standard provisions.

11. Recent Developments

• 1 May 2026: CTEC.L closed at 210.00p; market cap ~£4.10 bn; shares within ~1% of the 52-week intraday low (207.40p) and ~33% off the June 2025 high (311.20p).
• 21 April 2026: Berenberg Bank reaffirmed a Buy rating (target ~340p, per public reports). [This research excludes analyst price targets — noted as a market data point only.]
• 16 April 2026: Ex-dividend date for FY25 final dividend (5.367 US cents per share); payable 28 May 2026.
• 9 April 2026 — Capital Markets Day: ConvaTec unveiled the new "Accelerate" strategy — successor to FISBE. Reaffirmed medium-term targets: organic revenue 6–8%, mid-20s adj operating margin (24–26%), double-digit adj EPS growth, double-digit FCF/equity CAGR. Eight new product launches scheduled 2026–27 across all four care categories.
• 16 March 2026: RNS Director/PDMR Shareholding — Jonny Mason and Fiona Ryder sold shares to satisfy income tax and NI on vested LTIP awards (CEO sold 291,149 shares at £2.344, retained 270,355; CFO retained 14,272 after sell-to-cover).
• 10 March 2026: Publication of 2025 Annual Report; submitted to FCA National Storage Mechanism. Available on convatecgroup.com in ESEF, downloadable PDF, and interactive formats.
• 24 February 2026 — FY25 results: Revenue US$2,439 m (+6.5% reported, +6.4% organic ex-InnovaMatrix). Adj operating profit US$544 m (+12.1%). Adj operating margin 22.3% (+110 bp). Adj diluted EPS 17.6 cents (+16.0%). Reported operating profit US$316 m (down 2.7%) including the US$72 m InnovaMatrix Triad-intangible impairment. Net debt US$1,330 m / 2.0× adj EBITDA. FY25 dividend 7.244 cents (+13%). FY26 guidance: organic revenue ex-InnovaMatrix 5–7%; adj operating margin ≥23.0%; double-digit adj EPS. Medium-term (2027+) revenue target raised to 6–8% (from 5–7%). Shares jumped ~8% on the day on the medium-term target raise despite the InnovaMatrix writedown.
• 3 February 2026 — FDA Warning Letter: ConvaTec subsidiary Unomedical Devices, S.A. de C.V. (Reynosa, Mexico) received a Warning Letter following a remote regulatory assessment. Issues cited: inadequate complaint handling for leaking insulin infusion sets, inadequate device validation, and failure to report adverse events within 30 days. No production restrictions or product recalls.
• 1 January 2026: CMS skin-substitute LCDs took effect with InnovaMatrix priced at US$127.28/cm² — an ~80% reduction. FY26 InnovaMatrix revenue guided to ~US$20 m (vs US$69 m FY25).
• November 2025: Jonny Mason confirmed permanent CEO; Fiona Ryder confirmed permanent CFO.
• 27 October 2025: Karim Bitar (CEO since September 2019) passed away after a period of medical leave. Strategic mourning across the FTSE healthcare sector.
• 28 October–7 November 2025 — 10-month trading update: Year-to-date organic revenue +6.3% (ex-InnovaMatrix); FY guidance narrowed to 6.0–6.5% organic growth (from 5.5–7.0%); FY26 adj EPS double-digit reaffirmed; UBS noted "ConvaTec has de-risked 2026".
• 29 July 2025 — H1 2025 interim results: Revenue US$1,179 m (+6.0% reported, +6.8% organic ex-InnovaMatrix); Infusion Care H1 25 revenue US$227 m (+13.7%, +14.1% organic). Interim dividend 1.877 US cents.
• 24 July 2025: Aquacel ConvaFiber received US, EU, UK and Australia regulatory clearance — commercial launch H1 2026.
• 4 August 2025: Karim Bitar took medical leave; Jonny Mason named Interim CEO; Fiona Ryder named Interim CFO.

12. Key Dates Coming Up

Date	Event
21 May 2026 (Thursday, 14:00 BST)	2026 Annual General Meeting — 20 Eastbourne Terrace, London W2 6LG
28 May 2026	FY25 final dividend payment date (5.367 US cents per share; ex-date was 16 April 2026)
Late July / early August 2026 (expected)	H1 2026 interim results (FY24 H1 was reported 29 July 2025; FY25 H1 was 29 July 2025)
H1 2026	Aquacel ConvaFiber commercial launch (US/EU/UK/AU)
H2 2026	ConvaVac single-use NPWT commercial launch
October/November 2026 (expected)	10-month trading update (FY24 trading update was 5 November 2025)
Late February 2027 (expected)	FY26 full-year results (FY25 was reported 24 February 2026)
FY26 (current guidance)	Organic revenue growth ex-InnovaMatrix 5–7%; adjusted operating margin ≥23.0% (incl. ~20 bp tariff cost in H1 26); double-digit adjusted EPS growth; capex US$200–230 m. InnovaMatrix revenue ~US$20 m (~2% Group headwind, ~3% in H1 26).
Medium-term (2027+)	Organic revenue growth 6–8%; mid-20s adjusted operating margin (24–26%); sustainable double-digit adjusted EPS growth; double-digit FCF/equity CAGR.

Related links: Live charts · Economic calendar · Forum · Blog

Disclaimer: This content is for informational purposes only and is not investment advice. ChartsView does not use analyst price targets, ratings, or consensus estimates. All figures are sourced from ConvaTec Group plc press releases, RNS announcements, the FY2025 Annual Report and FY2025 Results presentation (24 February 2026), the H1 2025 Interim Results (29 July 2025), the Capital Markets Day (9 April 2026), the FDA Warning Letter (3 February 2026), CMS announcements, and public market data as at 1–4 May 2026. Always do your own due diligence.